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Abstract
Smad7 is a key negative regulator of the transforming growth factor b (TGF-b) signaling and plays an important
role in modulating a large array of biological processes. The physiological actions of Smad7 have been extensively
investigated by using various mouse models. These studies have pinpointed numerous important in vivo functions
of Smad7, including its activity in early embryonic development, fibrosis of many organs, skin cell differentiation,
regulation of immune response and inflammation, tumorigenesis, and metabolic control. As most biological
activities modulated by Smad7 are closely related to human disorders, it is anticipated that Smad7 will continue to
be an intriguing molecule that will be vigorously investigated in the future to strengthen our understanding about
the pathogenesis of human diseases.
Introduction
Members of the transforming growth factor b (TGF-b)
superfamily play essential roles in many physiological
and biological processes including embryonic develop-
ment, tumorigenesis, immunity, inflammation, and var-
ious physiologic courses [1]. The canonical signaling
event induced by TGF-b superfamily members is initiated
by ligand-mediated heteroligomerization of the serine-
threonine kinase receptors, which phosphorylate signal-
ing-restricted Smads (R-Smads), such as Smad2/3 for
TGF-bs and Smad1/5/8 for bone morphogenetic proteins
(BMPs). The activated R-Smads then form a heterocom-
plex with a common Smad (Co-Smad or Smad4) and the
complex is translocated into the nucleus, resulting in
transcriptional regulation of a broad repertoire of target
genes [2,3]. On the other hand, Smad6 and Smad7 fall
into the inhibitory Smad (I-Smad) subfamily that con-
tains Smad6, a relatively specific inhibitor for BMP sig-
naling, and Smad7, a general inhibitor for both TGF-b/
activin signaling and BMP signaling [4-6]. Originally,
Smad6 and Smad7 were discovered to be upregulated by
shear stress in human vascular epithelium [7]. Smad7
was first reported as an inducible antagonist for TGF-b-
mediated signaling upon TGF-b activation [5]. It was
found to stably associate with the TGF-b receptor com-
plex and block phosphorylation of Smad2/3 upon TGF-b
stimulation [5]. Smad7 antagonizes TGF-b signaling
through multiple mechanisms, such as by interfering
with the recruitment of R-Smads upon TGF-b/activin
activation [5,8], by inducing degradation of TGF-b type I
receptor after recruitment of E3 ubiquitin ligases [9-11],
and by recruiting protein phosphatase 1 (PP1) to the
receptor complex via interaction with growth arrest and
DNA damage protein 34 (GADD34) [12]. In addition to
its inhibitory activity to TGF-b/activin signaling, Smad7
was also found to be actively involved in mediating the
cross-talk between TGF-b signaling with other cellular
signaling pathways [13].
Since the identification of Smad7 fourteen years ago,
the physiological functions of Smad7 have been uncov-
ered mainly through two lines of studies. Firstly, dysre-
gulation of Smad7 has been demonstrated to be
associated with the pathogenesis of many human dis-
eases, including malignancy, scleroderma, and chronic
inflammatory bowel disease (IBD). Secondly, various
animal models have been used to unravel the physiologi-
cal activities of Smad7. In this review, we will mainly
focus on those discoveries pertinent to the physiological
functions of Smad7 by studies using mouse models.
Smad7 and embryonic development
The effect of Smad7 on mouse development has been
revealed by manipulation of Smad7 expression through
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and genetic deletion by knockout technology. Overex-
pression of Smad7 in mouse zygotes inhibits embryonic
development beyond the 2-cell stage [14]. Adenovirus-
induced overexpression of Smad7 into embryonic mouse
lungs in culture prevents TGF-b-mediated inhibition of
both lung branching morphogenesis and epithelial cell
differentiation, indicative of potential activity of Smad7
in lung development [15]. Transgenic overexpression of
Smad7 in the mouse skin disrupts hair follicle morpho-
genesis and induces premature sebaceous gland develop-
ment by antagonizing Wnt/b-catenin signaling [16]. It
was also reported that Smad7 inhibits chondrocyte dif-
ferentiation possibly by down-regulating BMP-activated
p38 mitogen-activated protein kinase (MAPK) pathways
[17]. Furthermore, neural crest-restricted Smad7 overex-
pression leads to defects in craniofacial and cardiovascu-
lar development [18]. Collectively, while these
overexpression-based studies may indicate that Smad7
has a function in early development, none of these stu-
dies could provide a definitive answer about the bona
fide activity of Smad7 during early development.
Currently, there are two reported mouse models with
embryonic deletion of Smad7 [19,20]. A hypomorphic
Smad7 mouse model was generated by Li et al. [19], in
which the exon 1 region of the Smad7 gene was deleted.
T h e s em u t a n tm i c ea p p e a r e dt oh a v en o r m a lp h e n o -
types, except for minor alterations in B-cell responses
[19], likely due to the observation that the Smad7 pro-
tein deleted of the Mad-homology 1 (MH1) domain
encoded by exon 1 retains the inhibitory activity on
TGF-b signaling [21]. The second Smad7 knockout
model was generated by depletion of exon 4 that
encodes MH2 domain of Smad7 protein and such dele-
tion completely abolished the inhibitory activity of
Smad7 on TGF-b signaling [20]. The majority of the
Smad7 mutant mice with exon 4 deletion died in utero
with multiple developmental defects in the heart, includ-
ing ventricular septal defect (VSD) and noncompaction
of myocardium [20]. Only a small percentage of these
Smad7-deficient mice could survive to adulthood,
accompanied by a severe decline of cardiac functions
and arrhythmia [20]. Therefore, it appears that the
major effect of Smad7 on embryonic development is
restricted to the cardiovascular system, especially the tis-
sues originated from the endocardial cushion, as Smad7
was found to be highly expressed in the cushion region
[22].
Smad7 and fibrosis
TGF-b has long been considered to be a master media-
tor of fibrosis in many organs including the lung, kid-
ney, pancreas, eyes, and liver. The established
understanding of fibrogenesis by TGF-b signaling is
initiated by the activation of Smad-mediated pathway
upon ligand binding, followed by myofibroblast transfor-
mation and stimulation of the synthesis of extracellular
matrix (ECM) proteins [23]. Various fibrogenic factors
have been demonstrated to participate in these pro-
cesses, including type I collagen, fibronectin, laminin,
and matrix metalloproteinases (MMPs). As the critical
negative modulator of TGF-b signaling, Smad7 has been
proposed to play a pivotal role in the protection against
TGF-b-induced fibrosis [24,25].
In the mice, overexpression Smad7 was first reported
to prevent bleomycin-induced lung fibrosis in an adeno-
virus-mediated gene transfer model [26], suggesting that
Smad7 may have applicability in the treatment of pul-
monary fibrosis. During the development of unilateral
ureteral obstruction (UUO) of kidneys in mice, a model
of progressive tubulointerstitial fibrosis, the protein level
o fS m a d 7w a sf o u n dt ob ep r o g r e s s i v e l yr e d u c e d[ 2 7 ] .
Interestingly, the reduction of Smad7 in UUO kidneys
was found to be caused by an increase in E3 ubiquitin
ligase and accelerated degradation of Smad7 protein
[27]. Consistently, deletion of Smad7 in the mice was
found to promote renal fibrosis in UUO kidneys [28]. In
addition to its effect on renal fibrosis, Smad7 has been
s h o w nt op l a yap r o t e c t i v er o l ei nf i b r o s i si no t h e r
organs. Pancreatic fibrosis is the hallmark of chronic
pancreatitis, currently an incurable disease. Smad7 also
possesses a protective effect on cerulein-induced pan-
c r e a t i cf i b r o s i sa sr e v e a l e d by overexpression of Smad7
in the pancreas using an elastase promoter [29].
Furthermore, it was found that Smad7 overexpression
could protect retinal pigment fibrosis in a proliferative
vitreoretinopathy mouse model [30].
Fibrosis has also long been considered a leading cause
of liver diseases following chronic liver injury. The final
common pathway of liver fibrosis is cirrhosis, character-
ized by accumulation of fibrillar interstitial collagens
type I and III, liver failure, and portal hypertension. Dys-
regulated TGF-b signaling is implicated in chronic liver
diseases [31]. In the mice, either overexpression or
down-regulation of Smad7 in the liver has been used to
investigate the effect of Smad7 on liver fibrosis. Ablation
of TGF-b signaling by overexpression of Smad7 specifi-
cally in hepatocytes is sufficient to blunt the fibrogenic
response after tetrachloride (CCl4) challenge and attenu-
ate liver damage [32]. On the other hand, reduction of
Smad7 expression could accelerate CCl4-induced liver
damage and fibrogenesis [33]. Collectively, these studies
have corroborated the protective function of Smad7 in
attenuating TGF-b-mediated fibrosis in multiple organs.
Smad7 in immune response and inflammation
As TGF-b is a critical regulator in immune and inflam-
mation responses [34,35], the potential function of
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extensively investigated. Whether Smad7 acts as an anti-
inflammatory factor or as a pro-inflammatory factor var-
ies with the context of the stimulating agent, microen-
vironment, tissue type, and disease model.
Smad7 has been found to possess a strong anti-inflam-
matory effect in various studies. Smad7 is able to sup-
press tumor necrosis factor a (TNFa) signaling pathway
through association with TGF-b-activated kinase binding
proteins (TAB2/TAB3) [36]. Consistently, transgenic
expression of Smad7 in the mouse skin is able to reduce
inflammatory response and nuclear factor B( N F B)
activation [36]. In agreement with such finding, overex-
pression of Smad7 in the kidney could attenuate both
renal fibrosis and inflammation in a mouse model of
autoimmune crescentic glomerulonephritis [37]. Smad7-
deficient mice developed more severe diabetic kidney
injury, characterized by a significant increase in microal-
buminuria, renal fibrosis and inflammation [38]. Consis-
tently, specific deletion of Smad7 in the mouse liver
enhanced inflammatory response upon alcohol adminis-
tration [39].
On the other hand, Smad7 was also found to have a
pro-inflammatory effect. Overexpression of Smad7 in
mature T cells enhances antigen-induced airway inflam-
mation and airway reactivity [40]. Engineered CD4+ T
cells with high expression of Smad7 have accelerated T
cell proliferation and activation, resulting in severe coli-
tis in the mouse [41]. Administration of Smad7 anti-
sense oligonucleotide leads to prevention or reversal of
inflammation in a colitis mice model induced by either
trinitrobenzene sulfonic acid (TNBS) or oxazolone [42],
consistent with the clinical findings that the TGF-b sig-
naling is impaired by elevated Smad7 expression in
inflammatory bowel disease (IBD) in humans [43]. In
addition, systemic administration of Smad7 antisense
oligonucleotide was able to suppress inflammation in an
experimental autoimmune encephalomyelitis (EAE)
mouse model [44]. Consistently, transgenic overexpres-
sion of Smad7 in T cells could accelerate EAE and
enhance T helper 1 response that was blocked by condi-
tional deletion of Smad7 in T cells [45].
Smad7 and tumorigenesis
TGF-b plays a dual role in cancer development, acting
as a tumor suppressor in tumor initiation in an early
stage but promoting tumorigenesis at a late stage by
promoting epithelial-mesenchymal transition (EMT),
migration, invasion and metastasis [3]. It was found that
genetic polymorphisms of Smad7 are associated with
human colon cancers [46,47]. In a chemical-induced
mouse skin tumor model, Smad7 was found to be over-
expressed [48]. These observations suggest that Smad7
might promote carcinogenesis in vivo.I n d e e d ,s u c ha
notion was supported by utilizing various mice models
with altered Smad7 expression levels. Overexpression of
Smad7 in primary mouse keratinocytes could cooperate
with oncogenic Ras to promote malignant conversion in
a mouse model for squamous cell carcinoma [49].
Smad7 overexpression in the pancreas was found to
induce premalignant ductal lesions [50]. Smad7 overex-
pression could also induce liver metastases using splenic
injection of nude mice with colon adenocarcinoma
(FET) cells that had overexpression of Smad7 [51].
Furthermore, overexpression of Smad7 in mouse airway
epithelium under the control of a mouse Clara cell spe-
cific 10 kDa protein (CC10) promoter could promote
formation of lung cancer formation upon urethane
treatment [52]. Collectively, these studies indicate that
Smad7 has a tumor-promoting function, most likely due
to its inhibitory effect on the tumor suppressor activity
of TGF-b.
Interestingly, Smad7 has also been reported to inhibit
tumor formation and metastasis as revealed by various
studies. Overexpression of Smad7 in breast cancer cells
led to reduction in metastasis and improvement of sur-
vival in tumor-bearing mice [53]. In a human melanoma
cell lines, ectopic expression of Smad7 was able to
reduce tumorigenesis as analyzed by xenograft experi-
ment in nude mice [54]. More recently, it was found
that overexpression of Smad7 in T cells was able to sup-
press colitis-associated tumors in the mice, accompanied
by elevated expression of interferon-g (IFNg) and accu-
mulation of cytotoxic CD8+ and Natural Killer (NK) T
cells in the tumors and peritumoral areas [55]. These
studies, therefore, have pinpointed a complex role of
Smad7 in tumorigenesis.
Smad7 in epithelium
The physiological functions of Smad7 in the skin have
been demonstrated by a number of studies. Keratin K5
promoter-induced overexpression of Smad7 specifically
in mouse epidermis shows multiple epithelial and devel-
opmental abnormalities at birth, exhibited as corneal
defects in the eyes, aberrant hair follicle morphogenesis
in the skin, epidermal hyperproliferation in the digestive
tract and severe thymic atrophy [16,56]. The epithelial
hyperplasia arisen in these Smad7 transgenic mice
might be contributed to increased cell proliferation and
aberrant apoptosis. Another mechanistic possibility
could be dysregulation of Wnt/b-catenin signaling, as
Smad7 was revealed to antagonize Wnt/b-catenin sig-
naling by accelerating b-catenin degradation such that
skin differentiation was shifted from forming hair folli-
cles to sebaceous glands [16]. In addition, transgenic
expression of Smad7 in the mouse skin could reduce
inflammatory response and NFB activation [36]. Col-
lectively, these studies reveal that Smad7 plays an
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matory response of the epithelium.
Smad7 in metabolism
It was recently discovered that Smad7 plays an impor-
tant role in b-cells, the insulin secreting cells in the pan-
creatic islets [57]. Conditional overexpression of Smad7
under the promoter of Pdx1, a gene that is specifically
expressed in pancreatic progenitor cells as well as in
adult b cells, could disrupt endocrine cell differentiation
in embryonic stage and cause overt diabetes when
Smad7 was conditionally induced in adult b-cells [57].
This study indicates that TGF-b signaling is critical for
homeostasis of adult b-cell functions, as the reduction
in insulin secretion and hyperglycemia caused by Smad7
overexpression could be rescued by restoration of TGF-
b signaling in the b-cells [57]. In a streptozotocin-
induced diabetic mouse model, deletion of Smad7 could
accelerate diabetic renal injury, likely caused by
increases in TGF-b signaling and NF-B-mediated sig-
naling pathway [38]. Consistently, overexpression of
Smad7 in diabetic rats could attenuate renal fibrosis and
inflammation [38]. Furthermore, hepatic deficiency of
Smad7 in the mice accelerates alcohol-induced liver
steatosis, likely caused by blunting of ethanol-induced
production of alcohol dehydrogenase 1 (ADH1) and
upregulation of critical genes involved in lipogenesis
[39]. Collectively, these studies indicate that Smad7 may
have a functional role in metabolic control.
Conclusions and perspectives
In the past decades, the physiological roles of Smad7
have been elucidated by using different mouse models
with either overexpression or deletion of Smad7 in dif-
ferent tissues/organs (Table 1). These studies have pin-
pointed various functions of Smad7 in a large array of
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ment, fibrosis of many organs, skin cell differentiation,
regulation of immune response and inflammation,
tumorigenesis, and metabolic control (Table 1). A few
conclusions could be drawn based on these in vivo stu-
dies. Firstly, it appears that a balanced expression level
of Smad7 is necessary for maintaining homeostasis dur-
ing embryonic development and for proper functionality
of many organs. For example, dysregulated Smad7
expression may cause severe developmental defects in
cardiovascular morphogenesis, lung branching, hair folli-
cle morphogenesis, and eye development. Secondly, the
major convincing evidence in terms of using overexpres-
sion of Smad7 as a potential therapy is the protective
roles of Smad7 on fibrotic damage through blocking
TGF-b-induced ECM production. Thirdly, the roles of
Smad7 in the regulation of immune response and
inflammation vary depending on the type of tissues/cells
and the nature of inflammatory stimuli. Fourthly, the
function of Smad7 on tumorigenesis is complex, depen-
dent on the tumor type and model system used in the
study. Whether Smad7 has a definitive role in tumor
progression and metastasis awaits application of more
sophisticated mouse models focused on analyzing late-
stage tumor development. Finally, it is noteworthy that
Smad7 may have other important physiological func-
tions yet to be discovered, such as its roles in different
facets of metabolic control. With the advances of cut-
ting-edge technology, it is anticipated that Smad7 will
continue to be an intriguing molecule that will be vigor-
ously investigated in the future, especially considering
its close relevance to human diseases.
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